CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices
IgGenix presents IGNX001 data at 2024 ASCIA
EURneffy approved in EU for needle-free anaphylaxis treatment
Crossject secures EUR6.9m French government grant to advance ZENEO Epinephrine
Celltrion USA submits CT-P39 Biologics License Application to FDA
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Allergy Therapeutics reports positive G306 Phase III trial results for Grass MATA MPL